

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3633596

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HEUN-SOO KANG	11/17/2015
SO-HYUN PARK	11/17/2015
YOUNG WOO PARK	11/17/2015
BUM-CHAN PARK	11/17/2015
DONG HEE LEE	11/17/2015
DONG JIN KIM	11/17/2015
SEON HA YUN	11/17/2015
KE SE LEE	11/17/2015
HYUN JU LEE	11/17/2015
KYUNG JIN KIM	11/17/2015
HEE CHAN KIM	11/17/2015
SEOK HO YOO	11/17/2015
MYEOUNG HEE JANG	11/17/2015
SEIL JANG	11/17/2015
YEONG WOOK SONG	11/17/2015
KI CHUL SHIN	11/17/2015
EUN YOUNG LEE	11/17/2015
EUN BONG LEE	11/17/2015
RECEIVING PARTY DATA	
Name:	METABOLIC ENGINEERING LABORATORIES CO., LTD.
Street Address:	6F., SEOUL UNIVERSITY COLLEGE OF MEDICINE INSTITUTE FOR CANCER RESEARCH
Internal Address:	101, DAEHAK-RO, JONGNO-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	110-744
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14893071

CORRESPONDENCE DATA**Fax Number:** (720)545-9888

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3035003399**Email:** DCha@HDCIPLaw.com**Correspondent Name:** DON CHA**Address Line 1:** 225 UNION BLVD**Address Line 2:** SUITE 150**Address Line 4:** LAKEWOOD, COLORADO 80228

ATTORNEY DOCKET NUMBER:	ERU-000300US
NAME OF SUBMITTER:	DON CHA
SIGNATURE:	/Don D. Cha/
DATE SIGNED:	11/26/2015
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 7

source=ERU-000300US_ASGNMNT#page1.tif

source=ERU-000300US_ASGNMNT#page2.tif

source=ERU-000300US_ASGNMNT#page3.tif

source=ERU-000300US_ASGNMNT#page4.tif

source=ERU-000300US_ASGNMNT#page5.tif

source=ERU-000300US_ASGNMNT#page6.tif

source=ERU-000300US_ASGNMNT#page7.tif

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 1 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

WHEREAS, we, Heun-Soo Kang of 1109-902, Raemian Echopalace Apt., 143, Gwanmun-ro, Gwacheon-si Gyeonggi-do 427-737, South Korea; So-Hyun Park of 42, Migeum-ro Namyangju-si Gyeonggi-do 472-913, South Korea; Young Woo Park of 506-104 Expo Apt., 448, Expo-ro Yuseong-gu Daejeon 305-761, South Korea; Bum-Chan Park of 106-1305 Hanbit Apt., 57, Eoeun-ro Yuseong-gu Daejeon 305-755, South Korea; Dong Hee Lee of 205Ho, 28-27, Gyeryong-ro 267 Seo-gu Daejeon 302-281, South Korea; Dong Jin Kim of 113-2101 Humansia Apt., 15, Waryong-ro 136beon-gil Yuseong-gu Daejeon 700-400, South Korea; Seon Ha Yun of 106-1206 Jindalrae Apt., 45, Wolpyeongdong-ro Seo-gu Daejeon 302-754, South Korea, Ke Se Lee of 4-33, Gyeryong-ro 264beon-gil Seo-gu Daejeon 302-281, South Korea, Hyun Ju Lee of 308-611 Songgang Chungsol Apt., 61, Songgang-ro 42beon-gil Yuseong-gu Daejeon 305-752, South Korea; Kyung Jin Kim of 125, Gwahak-ro Yuseong-gu Daejeon 305-806, South Korea; Hee Chan Kim of 125, Gwahak-ro Yuseong-gu Daejeon 305-806, South Korea; Seok Ho Yoo of Bio Diagnostics Convergence Center, Baejae Univ., 516, Daedeok-daero Yuseong-gu Daejeon 305-340, South Korea; Myeoung Hee Jang of 402Ho, 129, Hongdo-ro Daedeok-gu Daejeon 306-826, South Korea; Seil Jang of 402Ho, 129, Hongdo-ro Daedeok-gu Daejeon 306-82, South Korea; Yeong Wook Song of 402 Paragon Apt., 67, Nambusunhwan-ro 309-gil Seocho-gu Seoul 137-849, South Korea; Ki Chul Shin of 102 Gahoe-dong Gyeongnam Villa, 90, Bukchon-ro Jongno-gu Seoul 110-260, South Korea; Eun Young Lee of 303-G UN village, 74, UN village 3-gil Yongsan-gu Seoul 140-884, South Korea, and Eun Bong Lee of 55-208 Hyundai Apt., 401, Apgujeong-ro Gangnam-gu Seoul 135-906, South Korea are the inventors and have invented certain new and useful improvements of the invention described and set forth in the below-identified application for United States Patent:

Title of Invention:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof
Filing Date:	November 22, 2015
Application No.:	14/893,071
Attorney Docket No.:	ERU-000300US

WHEREAS, Metabolic Engineering Laboratories Co., Ltd., a corporation, having the principal office at 6F., Seoul University College of Medicine Institute for Cancer Research 101, Daehak-ro, Jongno-gu, Seoul 110-744, South Korea ("Assignee") is desirous of acquiring the entire right, title and interest in and to the invention, the application, and any and all Letters Patent or similar legal protection, foreign or domestic, to be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we transfer to Assignee, its successors and assigns, our entire right, title, and interest in and to the invention, the above-identified patent application, (including divisionals, continuations, continuations-in-part, and any other applications that claim the priority benefit of the above-identified patent application), corresponding foreign applications, all Letters Patent or similar legal protection issuing thereon, and all rights and benefits under any

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 2 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	



applicable treaty or convention; and we authorize the Commissioner of Patents and Trademarks of the United States or foreign equivalent thereof to issue the Letters Patent or similar legal protection to the Assignee.

Assignors further agree that we will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or assignee's successors and assigns.

Assignors and assignee hereby authorize and request Hamilton DeSanctis & Cha, LLP, 225 Union Blvd., Suite 150, Lakewood, CO 80228, to insert herein above the application number and the filing date of said application when known.

We hereby also declare that the above-identified patent application was made or authorized to be made by us. We believe that we are the original joint inventors of a claimed invention in the application. We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. §1001 by fine or imprisonment of not more than five (5) years, or both.

IN WITNESS WHEREOF, we have hereunto set our hands and affixed our seal on the date indicated below:

Date: <u>17 November</u>	 Heun-Soo Kang
WITNESSED BY:	
Date: <u>17 November</u>	 Kim Eun Young <Name of Witness>

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 3 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

Date:

17 November

So-Hyun Park

WITNESSED BY:

Date:

17 November

EUN-HEE KIM

<Name of Witness>

Date:

17 November

Young Woo Park

WITNESSED BY:

Date:

17 November

Chan-Young Kang

<Name of Witness>

Date:

17 November

Bum-Chan Park

WITNESSED BY:

Date:

17 November

SI-won Lee

<Name of Witness>

Date:

17 November

Dong Hee Lee

WITNESSED BY:

Date:

17 November

Sang-Young Rim

<Name of Witness>

PATENT


REEL: 037148 FRAME: 0406

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 4 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

Date:


17 November


Dong Jin Kim

WITNESSED BY:


Date:

17 November

Hwa-Jeong Do 
<Name of Witness>

Date:


17 November


Seon Ha Yun

WITNESSED BY:

Date:

17 November

Myung-jin Kim 
<Name of Witness>

Date:


17 November


Ke Se Lee

WITNESSED BY:

Date:

17 November

Jae-Woon Hwang 
<Name of Witness>

Date:


17 November


Hyun Ju Lee

WITNESSED BY:

Date:

17 November

Young-Min Kim 
<Name of Witness>

PATENT

REEL: 037148 FRAME: 0407

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 5 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

Date: 17 November 김정진
Kyung Jin Kim

WITNESSED BY:

Date: 17 November Young-Kyun Kim
<Name of Witness>

Date: 17 November 김찬희
Hee Chan Kim

WITNESSED BY:

Date: 17 November SungKyu Lee
<Name of Witness>

Date: 17 November Seok Ho Yoo
Seok Ho Yoo

WITNESSED BY:

Date: 17 November Jung-Hee Hwang
<Name of Witness>

Date: 17 November Myeoung Hee Jang
Myeoung Hee Jang

WITNESSED BY:

Date: 17 November Eui-Man Chung
<Name of Witness>

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 6 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

Date:

17 November

Seil Jang

WITNESSED BY:

Date:

17 November

Ji Eun Song

<Name of Witness>

Date:

17 November

Yeong Wook Song

WITNESSED BY:

Date:

17 November

Ji Yong Choi

<Name of Witness>

Date:

17 November

Ki Chul Shin

WITNESSED BY:

Date:

17 November

JooYoun Lee

<Name of Witness>

Date:

17 November

Eun Young Lee

WITNESSED BY:

Date:

17 November

Jihye Shin

<Name of Witness>

PATENT

REEL: 037148 FRAME: 0409

ASSIGNMENT

Attorney Docket No.:	ERU-000300US	Page 7 of 7
First Named Inventor:	Heun-Soo Kang	
U.S. Patent Application No.:	14/893,071	
Filing Date:	November 22, 2015	
Title:	Anti-TNF- α /CXCL10 Double-Targeting Antibody and Use Thereof	

Date:

17 November

Eun Bong Lee

WITNESSED BY:

Date:

17 November

YU JIN JUNG

<Name of Witness>